Cargando…

Impact of age on the toxicity of immune checkpoint inhibition

Indications for immune checkpoint inhibitor therapy are increasing. As the population ages, many patients receiving such drugs will be older adults. Such patients are under-represented in clinical trials, and therefore the safety of immune checkpoint inhibitors in this population has not been adequa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samani, Amit, Zhang, Shuai, Spiers, Laura, Suwaidan, Ali Abdulnabi, Merrick, Sophie, Tippu, Zayd, Payne, Miranda, Faust, Guy, Papa, Sophie, Fields, Paul, Van Hemelrijck, Mieke, Josephs, Debra H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545628/ https://www.ncbi.nlm.nih.gov/pubmed/33033183 http://dx.doi.org/10.1136/jitc-2020-000871

Ejemplares similares

How we treat neurological toxicity from immune checkpoint inhibitors
por: Spain, Lavinia, et al.
Publicado: (2019)

Toxicities associated with checkpoint inhibitors—an overview
por: Spiers, Laura, et al.
Publicado: (2019)

Optimising Multimodality Treatment of Resectable Oesophago-Gastric Adenocarcinoma
por: Suwaidan, Ali Abdulnabi, et al.
Publicado: (2022)

Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review
por: Van Hemelrijck, Mieke, et al.
Publicado: (2019)

Association Between Vitamin D and Novel SARS-CoV-2 Respiratory Dysfunction – A Scoping Review of Current Evidence and Its Implication for COVID-19 Pandemic
por: Santaolalla, Aida, et al.
Publicado: (2020)

Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity
por: Chin, Ik Shin, et al.
Publicado: (2022)

Anosmia and ageusia are emerging as symptoms in patients with COVID-19: What does the current evidence say?
por: Russell, Beth, et al.
Publicado: (2020)

COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?
por: Russell, Beth, et al.
Publicado: (2020)

Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence
por: Russell, Beth, et al.
Publicado: (2020)

Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study
por: Beckmann, Kerri, et al.
Publicado: (2019)

Systematic review of adherence rates by medication class in type 2 diabetes: a study protocol
por: McGovern, Andrew, et al.
Publicado: (2016)

Association between serum markers of the humoral immune system and inflammation in the Swedish AMORIS study
por: Santaolalla, Aida, et al.
Publicado: (2021)

Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma
por: Kuryk, Lukasz, et al.
Publicado: (2019)

Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors
por: Nuzzo, Pier Vitale, et al.
Publicado: (2020)

One Piece of the Jigsaw for the Cancer Recovery Strategy: Prevalence of COVID-19 in Patients With Cancer
por: Moss, Charlotte, et al.
Publicado: (2020)

Setting the scene – a future ‘epidemic’ of immune-related adverse events in association with checkpoint inhibitor therapy
por: Bermudez, Maria V, et al.
Publicado: (2019)

Circulating gamma-glutamyl transferase and development of specific breast cancer subtypes: findings from the Apolipoprotein Mortality Risk (AMORIS) cohort
por: Shackshaft, Lydia, et al.
Publicado: (2017)

Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade
por: Patel, Akshay J., et al.
Publicado: (2022)

Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study
por: Sollie, Sam, et al.
Publicado: (2019)

Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study
por: Sollie, Sam, et al.
Publicado: (2020)

Cancer staff in an NHS cancer center: infections, vaccination, stress and well-being support during the COVID-19 pandemic
por: Hadi, Hajer, et al.
Publicado: (2022)

Symptom relief of leiomyomatosis peritonealis disseminata with ulipristal acetate
por: Verguts, Jasper, et al.
Publicado: (2013)

Is There a Role for Exercise When Treating Patients with Cancer with Immune Checkpoint Inhibitors? A Scoping Review
por: Handford, Jasmine, et al.
Publicado: (2022)

Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma
por: Openshaw, Mark R., et al.
Publicado: (2020)

Immune checkpoint blockade in ovarian cancer
por: Weiss, Lukas, et al.
Publicado: (2016)

Chronic immune checkpoint inhibitor pneumonitis
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Association between COVID-19 burden and delays to diagnosis and treatment of cancer patients in England
por: Fox, Louis, et al.
Publicado: (2022)

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
por: Mamlouk, Omar, et al.
Publicado: (2019)

Toxicities of Immune Checkpoint Inhibitors: Itis-Ending Adverse Reactions and More
por: Ellithi, Moataz, et al.
Publicado: (2020)

Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices
por: Kinsella, Netty, et al.
Publicado: (2018)

Calreticulin couples with immune checkpoints in pancreatic cancer
por: Huang, Xing, et al.
Publicado: (2020)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020)

Management of Immune Checkpoint Inhibitor Toxicities
por: Durrechou, Quentin, et al.
Publicado: (2020)

IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma
por: Taylor, Chelsea A., et al.
Publicado: (2022)

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
por: Khair, Duaa O., et al.
Publicado: (2019)

Acute interstitial nephritis related to immune checkpoint inhibitors
por: Belliere, Julie, et al.
Publicado: (2016)

Management of adverse events related to checkpoint inhibition therapy
por: Rudzki, Jakob Daniel
Publicado: (2018)

Checkpoint inhibitor-related renal vasculitis and use of rituximab
por: Mamlouk, Omar, et al.
Publicado: (2020)

Safe provision of systemic anti-cancer treatment for urological cancer patients during COVID-19: a tertiary centre experience in the first wave of COVID-19
por: So, Alfred Chung Pui, et al.
Publicado: (2022)

Your next clinical cancer research project: preparation in a multidisciplinary environment is key
por: Van Hemelrijck, Mieke, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_iavvpk7tpoarjjas67a70g2ive